Strides Pharma Science Limited (STAR) Earnings Call Transcript & Summary
October 30, 2026
Earnings Call Speaker Segments
Operator
operatorLadies and gentlemen, good day, and welcome to Strides Pharma Science Limited Q2 FY '27 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Abhishek Singhal
executiveThank you, Narsi. Very good morning, and thank you for joining us today for Strides earnings call for the second quarter and half year ended September 2026. Today, we have with us Badree, Managing Director and Group CEO; and Vikesh, Group CFO, to share the highlights of the business and financials for the quarter. I hope you've gone through our results release and quarterly investor presentation that have been uploaded on our website as well as stock exchange website. The transcript for this call will be available in a week's time on the company's website. Please note today's discussion may be forward-looking in nature and must be viewed in relation to the risks pertaining to our business. After the end of this call, in case you have any further questions, please feel free to reach out the Investor Relations team. I now hand over the call to Mr. Badree to make its opening comments.
Badree Komandur
executiveThank you, Abhishek. Good morning, good afternoon, and good evening, everyone, and a warm welcome to the Strides Q2 and H1 FY '27 Earnings Call. Thank you for joining us and for the trust and support so many of you have shown us over the years. As always, I'll begin with the overview of the quarter and I'll share an update of our overall FY '28 aspiration followed by our U.S. and ex U.S. business. Vikesh will then take you through the financial performance in greater detail. After which we'll be happy to take your questions. Q2 FY '27 has been a quarter of first for Strides. We delivered our highest quarterly revenue, and for the first time in our history, our ex U.S. business became larger than our U.S. business. We a milestone we had set for FY '28, and I have reached well ahead of the schedule. Let me share the headlines first. Our overall FY '28 growth aspiration remains intact. Our [indiscernible] business is accelerating fast faster than the U.S. and well ahead of the schedule. Let me say that again, our overall revenue ambition for FY '28 is only in place. What will change is the regional mix with ex U.S. accelerating setting more than the U.S. Our goal for ex U.S. was to match the U.S. by FY '28, and we have achieved that in the Q2 of FY '27 itself. As we highlighted last quarter, we expect H2 to be stronger than H1. On the Q2 FY '27 performance, I'll cover the broad highlights. With this, let me take you through the quarter, and I'm delighted to report a strong second quarter. Revenue for Q2 FY '27 reached 14,297 million, our highest ever growing at 17% year-on-year and 13% quarter-on-quarter, led by our ex U.S. business and delivered against a challenging macro backdrop. Ex U.S. now contributes 49% of our revenues, up from 43% in Q2 of last year. The clear signs that our diversification strategy is delivering. Absolute gross margins grew a healthy 13% year-on-year to [indiscernible] million. Our gross margin stood at 56% compared to 57.8% in Q2 last year and 16.9% in Q1 this year, reflecting a higher input cost linked to the geopolitical situation. EBITDA grew 8% year-on-year to INR 2,509 million, crossing the INR 2,500 million mark in a single quarter for the first time. Another milestone for strides on the milestone for states. EBITDA margin was 17.6% compared to 19% in Q2 last year and 18.2% in Q1 as we absorbed the high material freight and logistics costs linked to the same geopolitical situation. We are actively addressing these cost pressures through an alternative hosting procurement initiatives and continuous cost optimization measures across the business, and we are confident in our ability to manage them. Operational PAT grew a strong 12% year-on-year to INR 1,358 million and an operational EPS rose to 14.7% from 13.2% in Q2 of last year. Before I move to our individual businesses, then let me step back and share an update on our FY '28 aspiration, which many of you will have already seen in our presentation. Let me begin with our track report because I think it tells our story better than any words I could use. Over the last 10 quarters, since Q1 FY '25, we have delivered a steady and predictable growth across key metrics. Revenue has compounded at about 14% and EBITDA at about 13% on operational PAT at about 41%. The consistency gives us a real confidence as we enter the next phase of our growth. We have that an aspiration of about $375 million in U.S. regional revenue by FY '28. Given how the market has award, we now expect to reach this a little beyond FY '28. The timing as smooth, the ambition has not. Importantly, our growth ambition for the rest of the company remains fully intact. Our U.S. market is accelerating well ahead of the plan, and we expect price to sustain the overall top line growth along with its profitability. On the U.S., the 1 thing that a smooth is the time line. The business continues to grow at a more measured pace and a recent line in the market rather than in our commitment. A few things have changed since we set this aspiration. First, the truck shortage opportunities in oral solids which lifted the industry at that time have largely normalized. Secondly, operating costs are higher with increased material costs and our decision to hold more inventory to sustain our industry-leading service levels. We also chose not to launch products that did not meet our margin or act to protect the profitability. And third, the growth in control substances is constrained by quota allocation, which we expect to improve progressively. Our response is rooted in our core business philosophy and rest on 3 pillars: first, the profitability led growth. We will protect our established profitability ratios and drive margin accretive revenues to selective launches and an expanding set of differentiated platforms. We will not compromise on the profitability or the quality of our business to chase revenue. Second, rebalancing our growth engines with a sharper focus on the ASUS to drive geographical diversification and accelerate overall growth. And third, the U.S. remains as a strategic growth market for us with growth anchored and differentiated platforms, such as nasal space, passes, wins and a steady expanding controlled substance portfolio. While our U.S. business has remained an anchor for us, the SBS business has grown up right alongside it. This is where we are seeing a real acceleration, our ex U.S. business grew 24% in H1 FY '27. Our goal for ex U.S. revenue to map the U.S. by FY '28. The U.S. was 76% of the U.S. business in FY '25, 90% in FY '26. And in Q2 FY '27, it reached 102%, crossing the U.S. well ahead of the schedule. That is a strategy patiently pursued for years and coming to life. Ex U.S. now stands equal with the U.S., not instead of it but alongside it, and the market that makes tries stronger as a whole. With growing scale, operating leverage and a better portfolio mix we expect the continued margin expansion in the business. As a result, we now have 2 strong growth engines, both pointing in the same direction. Our U.S. business is a foundation with deep market leadership, a broad approved portfolio and a growing pipeline of differentiated and controlled substance products. Our ex U.S. business is our accelerator with a strong presence across Europe, U.K., Nordic, Africa, a robust launch changing and a long runway into new territories. Both are covered by the same discipline, a deep pipeline, steady launches and a relentless focus on serving our customers. These 2 engines do not compete, they strengthen each other. They give us more ways to grow and make us more diversified and resilient. With that, let me take you through the -- through our U.S. business. Revenue for Q2 stood at 6,855 million or $173 million, growing 9% year-on-year and 9% quarter-on-quarter. For H1, the U.S. revenue was INR 13,327 million, up 7% year-on-year. As we indicated in our last call, we expected a softer first half and I'm encouraged by the healthy sequential recovery we delivered this quarter. Our B2B partner business saw a strong order book and we secured meaningful new business wins during the year from a partnered product, our recent launches and other key molecules in our portfolio. These wins will begin to show up in our performance over the coming quarters and underpin the better H2 we have been talking about. We continue to deliver industry-leading service levels to all our customers. This is a real competitive advantage, and it is central to winning and retaining business with some of the largest customers and partners in the market. Our portfolio gives us a strong foundation. As of October 26, we have filed 230 ANDAs, out of which 22 have been approved, covering 154 products. We also have a basket of ANDAs to be launched, and we'll commercialize these at an opportune time. During the quarter, we launched 3 products, taking our commercial portfolio to 75 products, up from 72 at the end of Q1. We now hold top 3 positions in 38 products, which together contribute approximately 70% of our revenues. As I mentioned earlier, our U.S. portfolio is steadily shifting towards higher-margin differentiated products. We have more than 40 value-accretive products in our active pipeline with filings and approvals planned in a phased manner on commercialization through Control substances is a key part of the strategy, and we see a much larger opportunity ahead. Our CS business saw higher customer orders in Q2. And today, our 5 commercialized CS products all overall solid tablets contribute to 6% of our revenues and address a market of around $750 million. While this portfolio is constrained by quota allocation, we have more than 10 CS products in our pipeline across multiple domains, including nasal space, patches, filings, which will expand our addressable market size to around 4.5 billion. above 6x the market we serve today. Importantly, these niche products need on the limited API quota, so they can drive the ramp-up of this business even within today's allocations. We also hold an advantage that takes years to build. Regulators require these products to be manufactured in the U.S. and our jesting facility already has the capacity and expertise to do exactly that. Beyond the control substances, we have more than 25 non-CF products to strengthen our core portfolio. Together, these products are set to broaden our addressable market, deepen our portfolio differentiation and create exciting medium- to long-term growth opportunities. Our near time milestones are already in sight. We continue to invest in building our acetate portfolio. And as committed in our last call, we filed our third nasal space, also a control substance in September 2026. Our nasal spray has good for our gold at in H2 FY '27, and we expect approval in Q4. In transdermal faces, we expect to launch a controlled substance patch in Q3. This product came to us as a part of the NDA we acquired and we expect its full benefit to flowing into in FY '28. Overall, we expect a better H2 for the U.S. business. We are committed, we are invested, and we are building for the long term, growing in a disciplined way that protects the quality of our earnings. Moving to the ex U.S. markets, our accelerator, the most exciting part of our story. The U.S. market for Q2 reached 663 million, an outstanding 31% growth year-on-year. For H1, the revenue was INR 2,838 million, up 24% year-on-year. Importantly, even as the ex U.S. markets grew faster than the company average, we maintain the profitability of this business. What [indiscernible] me most is how broad the growth is. Every U.S. ex U.S. market continues to show healthy momentum driven by new product launches and expansion of our core base into new geographical into new geographies and with new partners. In Q1, we have said that certain shipment delays are a matter of timing or not demand. I am pleased to say that with the robust supply chain execution, we delivered Q2 without any spillovers and demand on order books across our key U.S. markets have remained very healthy. In the U.K., our prescription business delivered a strong performance with healthy pricing volume momentum across several key molecules. We continue to deepen our relationship with the leading wholesalers in the market, positioning us as a dependable supply partner. We expect to launch -- we expect the launch momentum to pick up here and drive the next stage -- next leg of growth. In Europe, our partner business delivered a strong performance on the back of higher customer uptake. Our private label business OTC business in Germany continues to grow strongly with wider pharmacy reach and an expanding product portfolio. We are adding new customers across several countries and multiple new out presenting deals we signed in the first half, which will further strengthen our momentum. Focused R&D investments and a broader customer base will continue to fuel growth in that region. The Nordics delivered a strong quarter-on-quarter growth, led by a base portfolio. Our branded prescription business is showing very encouraging early signs of in the market -- in market uptake with some of our branded products now positioned as first-line treatment across several regions in Denmark and more regions expected to follow. Together with the increasing launch momentum, our branded portfolio has expanded to drive growth in the Nordics in the second half. In Australia, the supply contract improved meaningfully, and we have upgraded on new projects with our key partners, which are now at various stages of implementation. In Africa, our branded business in Francophone Africa delivered a stellar growth, and we continue to outpace the underlying market. Our deal with Sandoz is now awaiting antitrust approvals in a few countries, and we expect it to close in Q3. In South Africa, we saw a strong momentum in the independent pharmacy channel and added new products or new business with a leading retail pharmacy chain. Overall, the strong launch pipeline and an expanding customer base and a significant regulatory filings under the is underway across all of our territories. We expect the full ex U.S. business to keep growing faster than the company average. Before I close, I am delighted to share an important governance update. We are pleased to welcome Mr. Bairan Kapawala to our Board as an independent director. Byron is a chartered accountant with more than 3 decades of experience in financial reporting, audit taxation and corporate governance and Chad, the Audit Committee of eClub Services on 3M India. This appointment will further strengthen the board's financial oversight. And with it, independent directors is now to make up 6 of our 10 directors. Baram, welcome to Strides. Before I hand over to Vikesh, let me leave you with 1 clear message. Our overall growth story is intact. While our U.S. aspiration will take a little longer, our focus on growth is unchanged. We will continue to pursue top line growth across geographies without compromising on profitability. Our commitment to U.S. is equally unchanged. It remains a core market central pillar of our growth and are home to some of the most exciting opportunities in our pipeline. Our U.S. business is strong. Our U.S. ex U.S. business is accelerating. And together, they give us more ways to grow than at any point of time in our history. With that, I will hand it over to Vikesh to take you through the financial performance. Vikesh, over to you.
Vikesh Kumar
executiveThank you, Badree. Good morning, good afternoon, and good evening, and thank you all for joining us. Badree has taken us through the headline performance for the quarter. I will focus on the drivers behind our profitability, cash flows and balance sheet metrics. Starting with gross margins. our material costs rose to 44% of revenues in Q2 from 42.2% last year, reflecting the increase in raw material costs that Badree described. This moderated our gross margins to 56% for Q2. Importantly, for the first half, gross margin stood at a healthy 5.3%. Our ex U.S. businesses, which -- where we have maintained profitability even as it scaled continues to support the quality of our margins with cost increases now moderating and our cost improvement programs, including alternate sourcing and procurement initiatives gaining traction, we are confident of sustaining our H1 gross margins going forward. Even in this challenging environment, we remain committed to our margin discipline, launching only products that meet our profitability threshold and continuing to focus on the quality of our revenue growth. Our EBITDA for the quarter was INR 251 crores, our highest ever at a margin of 17.6%. Higher material, freight and supply chain costs linked to the geopolitical situation compressed our margins and tempered the flow-through of a very strong revenue growth, but it did not hold back the growth in our absolute profitability. With the 2 growth engines, U.S. and ex U.S. now contributing in balance, our earnings base is more diversified and resilient than ever before. On operating costs, other operating costs, excluding freight, increased by INR 47 crores year-on-year due to higher manufacturing and other operating costs in manufacturing and freight costs increased INR 21 crores year-on-year to 5.5% of revenues. Even with these cost increases, operating leverage is still visible as total operating costs improved by 40 basis points to 38.4% of revenues. In terms of cost line items below EBITDA, our depreciation and amortization was at INR 57 crores for the quarter and net finance cost was at INR 43 crores, slightly higher due to the higher average working capital borrowings we had during the quarter. Operational part grew a healthy 11.5% year-on-year to INR 136 crores with an operational EPS of INR 14.7 per share and our EBITDA to operational PAT conversion remained steady at 54%. Our reported PAT at INR 134 crores for the quarter with a reported EPS of 14.2 per share. From a H1 perspective, the first half delivered steady growth across all our key metrics. H1 FY '27 revenues grew 15.1% to INR 2,695 crores on EBITDA grew 6.9% to INR 481 crores with a 17.8% EBITDA margin and operational PAT grew 9.8% to INR 259 crores on with operational EPS of INR 28.1 per share. Reported PAT for the first half was at INR 300 crores, which was up 26.4% and this included the gain on pivot divestment, which we recognized in Q1. Moving to working capital. Our cash-to-cash cycle stood at 137 days. This is up 13 days from March 2026 with absolute working capital increasing by INR 307 crores during the first half. This reflects 2 components: investment in inventory to counter the elongated supply chain time lines and the working capital, which supported our growth. Approximately INR 174 crores reflects the 14 days increase, which we have seen in our inventory levels from Q4. This has been due to the higher transit and lead times due to the geopolitical situation and we also had a deliberate increase in our finished goods inventories at all our front-end locations. This has helped us get back to the industry-leading service levels in our tough operating environment. These service levels have been central to the new business wins we secured in the U.S. in this quarter and also delivering growth on our ex U.S. markets. The remaining INR 133 crore increase in working capital is on account of the 15% revenue growth we achieved in H1. We remain steadfast in our efforts to continuously improve our cash to cash cycle and get them back to our historic levels. On net debt, as we had earlier indicated, the inventory build over the last 2 quarters was expected to lift our net debt-to-EBITDA ratio temporarily the ratio now stands at 1.72x, reflecting the INR 211 crore increase in net debt during H1 driven by working capital. At the same time, we continue to invest in our future, deploying INR 208 crores in CapEx and intangibles to support our growth platforms including our nasal pray and transdermal patch programs, these investments are directed at differentiated at the differentiated pipeline Badree outlined, including our controlled substances opportunity, which will broaden our addressable market and support margin accretive growth. As inventory normalizes and H2 launches and business wins begin to contribute, we remain continue -- we remain focused on growth and improving our cash-to-cash cycle. With this, we expect our net debt-to-EBITDA ratio to stabilize and improve by the end of the year. This net debt is not adjusted for the retained investment we hold in OneSource, which is now valued at approximately INR 290 crores. On ROCE, our trailing 12-month ROCE was at 14.4%, remaining in the 14% to 15% range as our growth continues and recent investments mature we expect these returns to improve. To summarize, Q2 delivered record revenues and EBITDA in a challenging cost environment, and the first half saw steady growth across all our key metrics with both our U.S. and ex U.S. business contributing in tandem. As we enter the second half, our priorities are clear: build on our growth momentum across these markets. preserve our gross margins, improve our cash to cash cycle and strengthen our net debt-to-EBITDA ratio. With the overall growth aspiration for FY '28 being intact and operating leverage playing out, we continue to maintain that bottom line should accelerate ahead of top line. We are confident in the strength of our business and in our ability to deliver on these priorities. Thank you, and we are now happy to take your questions.
Abhishek Singhal
executiveNadri, we open for Q&A please.
Operator
operator[Operator Instructions] The first question is from the line of Nitin Agarwal from DAM Capital.
Nitin Agarwal
analystBadree, you already talked about in opening comments around the pickup, which is happening in the non-U.S. market. But 2 things. One is, a, if you can just give us a sense on what is leading to this improved momentum in the non-U.S. markets. And two, what kind of growth is possible in these markets over the next say 2 to 3 years period, especially with the -- taking into account the Sandoz transactions you've closed, as you said sometime this year?
Badree Komandur
executiveYes. So as far as the non-U.S. market is concerned, this is a market we are invested for a very long period of time, the portfolio expansion, expansion in the new territories drives these markets. There are B2C markets, there are B2B markets and we see an increased demand. And we believe that these are the main 2 reasons that we really feel that this market can expand. We have got a portfolio in place products in place. Regulatory is very minimal from that standpoint for the commercial revenue and we are also investing in domains, which are in these markets. And overall, I think it's all adding up quite well. That's the first part. As far as the growth in these markets, we'll continue to do grow at much more than the company average on all of these markets. On the higher side, we always said that this market will grow faster than the U.S. market in the last -- for the last few conversations. And we think that trend will continue. And this trend is going to continue for the near term. And with the Sandoz adding in, it will definitely lead to a very, very meaningful size in the next 1 or 2 years. And we are very sure of mirroring the U.S. market in terms of the aspiration that was an aspiration, which we kept about 2 years back from $375 million perspective with the latest trends that is coming in the non-U.S. markets, it should be upwards some time.
Nitin Agarwal
analystSo it should be upper 370s or F 28 is what you meant, if I got it right?
Badree Komandur
executiveThat's correct.
Nitin Agarwal
analystAnd are these -- the growth in these markets? Is it driven by some specific products? Or this is like a broad-based product portfolio which is driving it?
Badree Komandur
executiveIt's a broad-based portfolio. As I said, there are B2C markets, B2B markets. think the good part is like the -- it's very sticky. It's very consistent. So 1 to reach a particular size, the stickiness will be much, much more. And the -- our product strategy has played out in all of these markets. And B2C markets, in fact, a lot of markets are in different stages of evolution. And that is what is driving the growth. Some markets are less than 25 million, 30 million, where the growth rates can be much higher and some markets are upwards of 50 million. where the growth rates maybe in the mid-teens. So that's what is driving the entire growth. It's a broad-based growth. And we are happy with the progress that we have achieved on the ex U.S. markets.
Nitin Agarwal
analystAnd Badree, on the profitability front, how do these markets compare versus the U.S. as a block?
Badree Komandur
executiveIt should be slightly higher than the company average in terms of the EBITDA because the -- it depends on the B2B as well as the B2C markets. Overall, I think the gross margins and the EBITDA good in these markets.
Nitin Agarwal
analystAnd secondly, on the U.S., you talked about things sort of catching up with a bit of a lag and the focus being more on some of these differentiated products. So when do you see the meaningful contribution from these new differentiated products begin to deliver?
Badree Komandur
executiveIt will be in FY '28, '29 for sure. That's what we are aiming for. It's 1 year a slight delay by about 3, 4 quarters, and we should be able to get to that get to that milestone by FY '29.
Operator
operatorNext question is from the line of Pranav from JM AMC.
Unknown Analyst
analystAm I audible? .
Badree Komandur
executiveYes, you are audible.
Unknown Analyst
analystSir, first question is on gross margins. So we've seen a sequential gross margin gross abound you're alluding that second half gross margin will be a bit better. So what gives you the confidence? Has anything particularly changed over here vis-a-vis second quarter?
Badree Komandur
executiveVikesh, you would like to take it up?
Vikesh Kumar
executiveYes. So from a quarter perspective, a lot of the purchases that if you would see, which came in Q4 at the height of the geopolitical disruptions, those did get consumed in this quarter. And we've also had a lot of cost initiatives that we had already put it in place when the geopolitical disruptions happened, and those have started playing out. We see them internally, and that is what we expect. It should start to play out from H2 as well and which is why we are confident that the margins at 58% are sustainable.
Unknown Analyst
analystSir, just extending over here. So do you think Q3 will be better than Q2 and Q4 better than Q3. So are we -- do you expect a sequential improvement or a sharp bump up in the fourth quarter or something?
Badree Komandur
executiveThe way I would say is our focus remains on EBITDA and that is what we will continue to focus on. We've grown our focus over the last many quarters has been to drive sequential growth. And we will continue to focus on that. So when you look at a longer-term trajectory, you will see us growing quarter-on-quarter.
Unknown Analyst
analystOkay. Second, on the guidance front that we've deferred to FY '28. Does your guidance hinge on, say, a particular set of products, if you can call out a product?
Badree Komandur
executiveSo first of all, it was not a guidance. What we mentioned was an aspiration for us to get to FY '28, so that is what we were chasing. With the geopolitical disruptions that have happened over the last few quarters and the fact that the shortages are no longer as much in the U.S. in the product portfolio that we operate in. And we did not want to launch products compromising our fabric of profitability discipline. And that is the reason we felt that it is better to protect the quality of margins and focus on profitability, drive the profitability and EPS margin accretion that we have been known for, for the last many quarters. And that is what we remain focused on.
Unknown Analyst
analystOkay. So on the aspiration front, does your aspiration films on a particular product or a particular opportunity or is it broadbase?
Badree Komandur
executiveIt does not hinge on a particular product. It is more broad-based, and we also spoke about the portfolio that we are building out, which will start to play out from FY '29.
Unknown Analyst
analystGot it. Got it. And sir, what gives you the confidence that your quota allocation for controlled optics will improve in the coming year?
Badree Komandur
executiveSo in fact, when you look at the last couple of years, right, we have seen progressive improvement in the quota allocations that we've received and quota allocations happen twice a year. And every time we've gone back with quota allocations with the history of our sales and the improvement in our sales, we've been able to get improved quota which is effectively what is reflected in the business today, which has grown from 0% to 6% in the last couple of years. It is a very different model than the regular retail products where you can get to a 20%, 30% market share overnight. This takes time. But then once you're in there, it remains sticky. And what we are also doing is having learned from this, we are building a portfolio around this entire controlled substance space, and plus the new product that we are building, they need very limited API quota, that would also give us an ability to ramp up much faster than the ramp-up that we have had over the last couple of years on the existing portfolio.
Operator
operator[Operator Instructions] Next question is from the line of Aksha Shinde from Centrum Broking.
Unknown Analyst
analystNow the ex U.S. revenue has surpassed the U.S. business. How should we look at the change in geographical mix from the margin perspective? Does the higher contribution from ex U.S. market have a structural impact on gross margin going ahead?
Badree Komandur
executiveYes. So as far as the overall gross margin is concerned, Vikesh highlighted that we will be in the range of that 58% to 60%, and we continue to maintain that range. As far as the U.S. markets are concerned, there are different types of pockets, B2B markets, B2C markets at various levels of profitability. And we believe that overall, every market will be healthy in terms of margins, and we will be within the range at the company level.
Unknown Analyst
analystUnderstood. And as the company is now maintaining higher inventory to navigate in place supply chain, so should we expect that working capital requirements to remain elevated? Or do you see the cash conversion cycle improving over the next few quarters?
Badree Komandur
executiveYes. Cash conversion cycle definitely will improve in the coming quarters. But as you know that last 6 months has been difficult for every company's every company operating in this space with the lead times increasing for the raw materials plus the key starting materials. And the main objective of most of the companies, including all of us, is to maintain the business continuity and keep the growth intact. And that's the reason we have increased the inventory levels. We believe that it will also -- it will form a new normal in some point of time. But what you're seeing is slightly at an elongated level at this point of time. But this will all moderate as we go along and we complete this year. We believe that the cash cycle engine should be back in the next quarter itself.
Unknown Analyst
analystOkay. Okay. And sir, lastly, on interest costs. So given the higher working capital borrowings and the ending the increase in interest cost during the quarter, should we expect this final cost to remain elevated for the H2 FY '27 as well?
Badree Komandur
executiveIt will be within a range between that INR 40 crores to INR 45 crores. It can be within the trains. And I think this quarter was about 46%, I think, if I remember, right? 43. So it will be within that 40% to 45% range.
Operator
operatorNext question is from the line of Karan Shah from GEC.
Unknown Analyst
analystTwo questions. I guess we alluded on the first quarter call that there was some deployment in revenue in the ex U.S. business. So would it be possible to quantify how much could have been the flow through to the second quarter?
Badree Komandur
executiveYes. So the flow-through has been -- as we have said, I think there is a slight -- I need to give you more clarity on this. Between the Q2 to Q1, okay, there have been certain supply issues. All that has been sorted out and that's what is being reflected in the growth. And if you really see the -- it is a very sticky business. we have sorted out for all the revenue recognition issues, whatever we had because of the long lead times because of which we could not reach the products on time. That has all been normalized and it's back to growth.
Unknown Analyst
analystSo can this be considered as a new run rate ex of Sandoz?
Badree Komandur
executiveYes.
Unknown Analyst
analystGot it. And sir, second question on CapEx. Any guidance for FY '27 and '28, what would be our CapEx?
Badree Komandur
executiveRakesh, you would like to take that up?
Vikesh Kumar
executiveYes. I mean it should be around the INR 300 crore mark. I mean, we've -- if you look at our spends have reduced from Q1 into Q2 and we expect it to be more closer around the INR 300 crore mark by the end of the year.
Unknown Analyst
analystAnd the same thing for FY '28?
Vikesh Kumar
executiveYes. FY '28 can be slightly lower.
Unknown Analyst
analystAnd a lot towards go towards the intangible, because I don't think we'll be requiring much maintenance.
Vikesh Kumar
executiveIt is -- there is maintenance CapEx that continues. So it will be maintenance CapEx and then some parts to intangibles, yes.
Operator
operatorNext question is from the line of Pratik from Unique PMS.
Pratik Kothari
analystSo the first half, we see about INR 265 crores of CapEx as per our cash flow. So does this include the IP purchases? Does it flow through your [indiscernible]?
Vikesh Kumar
executiveYes. So the 260 the difference between the INR 200 crores and the INR 260 crores is the INR 60 crores of payments were for all the investments that were done last year, the cash flows went out in the first half.
Pratik Kothari
analystOkay. But this INR 200 crores, does it include IP purchase or this is...
Vikesh Kumar
executiveYes. This includes IP purchase as well. This includes IP purchase as well as the investments that we are doing in nasal sprays and patches.
Pratik Kothari
analystAnd even last year, we had done a few IP purchase, a few external R&D partnerships Sandoz, so all of that, when does that start contributing or -- Sandoz I believe is yet to the rest and is that coming?
Vikesh Kumar
executiveSo some of them are for our global markets, and they are playing out as far as the ex U.S. is concerned. Some of the specifics for U.S. are -- will come through. In fact, we are going to launch our first patch later this year. which was an acquired IP last year. So some of these will start to flow through as far as the U.S. is concerned over the next 18 months or so. But as far as ex U.S. is concerned, it is already playing out.
Pratik Kothari
analystGot it. Fair. And so effectively in the last 6, 8 quarters, we have kind of a investments, be it CapEx, IT purchases, acquisitions, RN programs. And that has kind of kept debt levels in a ballpark range. And we earlier had some aspiration of being debt free or net debt free in a certain thing. So has that changed? Are we pushing that out? I mean, are we now choosing to invest more rather than pay down debt and maybe we are at comfortable levels. So FY '28 or '29, nothing used to be earlier in guidance or aspiration?
Vikesh Kumar
executiveYes. So that aspiration has not changed. And if you really look at the increase in debt level, it has been largely working capital driven than CapEx driven, right? The increase in our working capital in the first half has been about INR 300 crores and almost INR 170 crores of it was on account of the geopolitical disruptions, which was more like a one-off. So surely, this is not a permanent thing. So our aspiration remains, our growth on a consolidated basis is intact. While the mix between U.S. and ex U.S. has changed on a consolidated basis, it is intact, and that will reflect in our cash flows and debt. And we will -- it will largely remain working capital debt as we get to '29.
Pratik Kothari
analystBut this plan that we have included working so that or was that ex of that?
Vikesh Kumar
executiveYes. I mean if you run the cash flows, you will get to that answer, right?
Pratik Kothari
analystNo, [indiscernible]. Yes.
Vikesh Kumar
executiveEffectively, what you are seeing the increase, if you see over the last 4 or 5 quarters, consistently reduced every quarter, right? This is the first quarter where you're seeing a debt increase. that debt increase has largely got to do with the working capital. So if we adjust for that one-off, we will -- you will start to see the cash flow and the cash flow that we deliver will continue over the next many quarters as growth continues.
Pratik Kothari
analystAll right. Fair. And last, again, in this cash flow statement, you see a INR 70 crores of some inventory obsoletion costs that we've charged to P&L. So anything on that?
Vikesh Kumar
executiveThere's nothing specific as that. I mean some of those are elements of the businesses that we operate in. I think on an overall basis, it is about 1%, 1% to 2% of COGS.
Pratik Kothari
analystNo, [indiscernible] for H1.
Vikesh Kumar
executiveBecause it is not -- I mean, it is a movement of provision. It is more from a reporting requirement that has been called out separately. So it is a cumulative number.
Pratik Kothari
analyst[indiscernible] cash flow segment?
Vikesh Kumar
executiveThe corresponding adjustment is in the inventory line in the inventory movement. So earlier, historically, that inventory movement was net. Now it has been grossed up for that line. I think it's more a presentation change.
Operator
operator[Operator Instructions] Next question is from the line of Kusum Agarwal, an individual investor.
Unknown Attendee
attendeeMy question was regarding the visibility of 2 U.S. launches. So the deck says that H2 will be -- it will be stronger because of new launches. I just wanted to get clarity on how many approvals and launches do we expect in the second half of financial year?
Badree Komandur
executiveRakesh, do you want to take it up?
Vikesh Kumar
executiveYes. So we expect to launch 4 to 6 products more importantly, the products that we already launched will also see revenues in H2. And therefore, we expect our H2 to be stronger than H1 and the H2 launches to flow in into FY '28, right, where we'll have a full year benefit for FY '28.
Operator
operator[Operator Instructions] Next question is from the line of Jayasam from Equitas.
Unknown Analyst
analystSo I just wanted to check, our U.S. business on dollar terms has actually been flat this quarter. So is it that missing a lot of price erosion? Or is it that you have discontinued through products because of margin requirements. So what is the reason for the revenue being flat year-on-year?
Vikesh Kumar
executiveSo see, from a revenue perspective, while on a dollar term, it has got to do more with the mix of products? And 2 is surprising in the market also gets adjusted to the current depreciation that happens with the competitive forces because as you know, in the U.S. market, the customers constantly won the best pricing. So that does get adjusted and which is why we remain focused on delivering the gross margin and having the pricing discipline and the profitability threshold as a framework as we run our P&Ls.
Unknown Analyst
analystSo it's mostly price and that is being offset by our probably new launches?
Vikesh Kumar
executiveAnd the cost improvement plans that we put in place.
Unknown Analyst
analystYes. But that can be on the bottom end, I'm talking about the [indiscernible] 73 million or 73 million. So we are basically fighting of price erosion with new launches. That's it, right?
Vikesh Kumar
executiveIt is not -- it will not be price erosion. It will also be some volumes also [indiscernible] give up, right? So it's a combination of both. So it is it may not be as much price erosion.
Unknown Analyst
analystOkay. Got it. And like somewhere in the PPD mentioned that like -- we are seeing that the drug shortages have normalized. And like death do you think those strategies [indiscernible]?
Badree Komandur
executiveWe lost you, but we can't hear you well. Can you please repeat your question?
Unknown Analyst
analystYes. So I just wanted to check, like in the PPT, you mentioned that the drug shortage opportunities have largely been dissipated. So are we expecting that to remain like that? Or do you see that shortages could come back when price erosions upper?
Vikesh Kumar
executiveI mean, see, that is more -- that would be more tactical at this point of time and which is where we're building a more strategic portfolio orientation. And as far as the shortages are concerned, supply levels across the industry have significantly improved over the last couple of years, the number of regulatory approvals have improved and which is effectively what has led very minimal shortages across most of the oral products that are there. I mean, the shortages that we see are either in injectables or in patches that continue to have shortages. So at this point, we are more focused on building that portfolio that can carry us and give more predictability of our growth.
Unknown Analyst
analystGot it. And could you on the controlled substance front. So when you say when we were going back to the regulator and asking for the higher codeine have always got it. So that additional volume that you get because the market shares from other sales in the market?
Vikesh Kumar
executiveYour voice is breaking out.
Unknown Analyst
analystCan you hear me now?
Badree Komandur
executiveYes.
Unknown Analyst
analystYes. So quickly on the controlled substance, and we say that whenever we go to the regulator price or and we get higher quotas, so that higher volume that you're getting, is it that the market is expanding? Or do you think that is got to do more with market share gains from other players in the market?
Vikesh Kumar
executiveIt has got to do more with market share gains in the market that we write.
Unknown Analyst
analystGot it. Just lastly, quickly on the LatAm front. Just wanted to understand how do you view LatAm, do you think it could be meaningful over the years? And what is the competition intensity in those markets? We know that there are a few listed players that are very strong in those markets. But how -- what is our strategy going into the Latin America markets?
Badree Komandur
executiveI can answer that question. We are in this regulatory phase of this market and it will take a couple of years for us to build. If at all, we -- I mean we have started building those markets I don't think so it will contribute meaningfully to any growth until about 29%, 29% 30%, maybe the first year. And we are in the process of building the portfolio.
Operator
operatorThat was the last question for today. I now hand the conference over to the management for closing comments.
Badree Komandur
executiveThank you, everyone, and good day to you. Thank you.
Operator
operatorThank you. On behalf of Strides Pharma Science Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Strides Pharma Science Limited transcript — plus 260,000+ transcripts from 13,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Strides Pharma Science Limited earnings transcripts and 260,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Strides Pharma Science Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.